Sterility Clinical Trial
— CLBROfficial title:
A Prospective, Randomized Controlled Study to Investigate the CLBRs of GnRH Antagonist Protocol Compared With the Standard GnRH Agonist Long Protocol for Controlled Ovarian Stimulation in Supposed Normal Ovarian Responders
This is a Phase IV, prospective, randomized controlled study to investigate the cumulative live birth rates (CLBRs) of gonadotrophin-releasing hormone (GnRH) antagonist protocol (GnRH-ant group) compared with the standard GnRH agonist long protocol (GnRH-a group) for controlled ovarian stimulation in supposed normal ovarian responders.
Status | Recruiting |
Enrollment | 888 |
Est. completion date | July 31, 2022 |
Est. primary completion date | October 30, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 38 Years |
Eligibility |
Inclusion Criteria: - Infertile women planning to undergo IVF/ICSI cycle using conventional GnRH agonist long protocol or GnRH antagonist protocol - Age = 38 years old - Basal AFC 8~20 - Basal FSH=10 IU/L - Basal E 2 <200pmol/L - Normal uterus and at least one side of the normal ovary - Informed consent form signed - Willing to follow the study protocol, and able to complete this study Exclusion Criteria: - Previous IVF/ICSI cycles >2 - Severe hydro-salpinx (Ultrasound shows hydro salpinx?2cm) - Severe endometriosis (Grade III - IV) - Polycystic ovarian syndrome (PCOS) - History of recurrent miscarriages (>2 times of miscarriages) - Plan to undergo ovarian stimulation for preimplantation genetic diagnosis or preimplantation genetic screening, oocyte donation, and social or medical freezing of oocytes - Any major systemic disease that as per Investigator's discretion precludes subject for participation in the study - With pregnancy contraindications - Alcoholism, drug abuse, drug addiction or patients with uncured sexually transmitted disease - According to the judgment of the Investigator, any medical condition or any concomitant surgery/medications that would interfere with evaluation of study medications - Simultaneous participation in another clinical study - Plan to use urinary gonadotrophin during COS treatment |
Country | Name | City | State |
---|---|---|---|
China | The second hospital of Hebei Medical University | Baoding | Hebei |
China | Peking University Third Hospital | Beijing | Beijing |
China | Jiangsu Provincial Hospital | Nanjing | Zhejiang |
China | The third hospital of Zhengzhoui Medical University | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Peking University Third Hospital | Fountain Medical Development Co., Ltd., Guangzhou KingMed Center for Clinical Lab.Co., Ltd, Merck Serono GmbH, Germany |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the cumulative live birth rates | To investigate the cumulative live birth rates in infertile women = 38 years old with normal ovarian from one initiated COS cycle. reserve using GnRH antagonist or agonist protocol for COS in ART treatment Numerator is the No. of women got their first live birth, the Denominator is the No. of women who attempt the ovarian stimulation. There will be two ways to calculate the CLBR: The conservative estimate of the cumulative live birth rate, which is based on the assumption that none of the women who do not return for a subsequent embryo transfer would have had a live birth. The optimal estimate of the cumulative live birth rate, which is based on the assumption that women who do not return for a subsequent embryo transfer would have had the same live birth rates as those who do return. |
two years | |
Secondary | Number of oocytes retrieved | recorded Number of oocytes retrieved on DOPU | 24 hours after Oocytes pick up | |
Secondary | Good-quality embryo rate (The Istanbul Consensus29) | Total the number of good quality embryos divided by Total the number of embryos | 24 hours after Oocytes pick up | |
Secondary | hCG positive rate | Numerator is the No.of ß-hCG blood test which is positive results, he Denominator is the No. of ß-hCG blood test. HCG test is Serum ß-hCG test after 11 to 17 | after 11 to 17 days of ET | |
Secondary | Implantation rate | the number of gestational sacs observed divided by the number of embryos transferred | 4 to 6 weeks after ET | |
Secondary | Clinical pregnancy rate | the number of clinical pregnancies expressed per 100 initiated cycles, aspiration cycles, or embryo transfer cycles. Note: When clinical pregnancy rates are given, the denominator (initiated, aspirated, or embryo transfer cycles) must be specified. | after 4 to 6 weeks of ET | |
Secondary | Ongoing pregnancy rate | the number of . Ongoing pregnancy divided by the number of Clinical pregnancy . Ongoing pregnancy is intrauterine pregnancy continued for 12 gestational weeks (detection of presence of gestational sac with fetal heartbeat by transvaginal ultrasound examination in week 12). | after 12 weeks of ET | |
Secondary | Live birth rate | Numerator is the No. of women got live birth resulting from fresh cycle (multiple births considered as one live birth), the Denominator is the No. of women who attempt the ovarian stimulation. | two years | |
Secondary | Cumulative clinical pregnancy rate | Numerator is the No. of women got their first clinical pregnancy, the Denominator is the No. of women who attempt the ovarian stimulation. | two years | |
Secondary | Miscarriage rate | the number of Miscarriage which is the natural death of an embryo or fetus before it is able to survive independently divided by the number of Clinical pregnancy . | after 12 weeks of ET | |
Secondary | Ectopic pregnancy rate | the number of .extrauterine pregnancy divided by the number of Clinical pregnancy . | after 4 to 6 weeks of ET | |
Secondary | Cycle cancelled rate and reason | Cancelled cycle is an ART cycle in which ovarian stimulation or monitoring has been carried out with the intention to treat, but which did not proceed to follicular aspiration or, in the case of a thawed embryo, to embryo transfer. Cycle cancelled rate is the number of Cancelled cycle divided by the number of embryos transferred. | On ART cycle | |
Secondary | severity of OHSS | Assessed the severity of OHSS. | two weeks after Oocytes pick up | |
Secondary | Rate of OHSS | the number of OHSS divided by the number of ovum pick up. Assessed the severity of OHSS. | two weeks after Oocytes pick up | |
Secondary | Time to pregnancy | time from Gn Initiation to the first clinical pregnancy. | 4 to 6 weeks after ET | |
Secondary | Time to live birth | time from Gn Initiation to the first live birth | nine months after pregnancy | |
Secondary | the Safety | Data on AEs will be collected at scheduled and unscheduled visits, based on information spontaneously provided by the subject and/or through questioning of the subject. | Two years after signature of informed consent |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01955356 -
Embryo Implantation After Induced Endometrial Injury
|
N/A | |
Completed |
NCT01330771 -
Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP
|
N/A | |
Completed |
NCT01330784 -
Assessment of the Therapeutic Utility of hMG-HP
|
N/A | |
Active, not recruiting |
NCT05079685 -
HyFoSy Versus HSG as a Diagnostic Technique for Tubal Patency.
|
||
Completed |
NCT04605003 -
Effectiveness of Nasal Endoscope Sterilization Using a Novel Rig-S™ Device
|
N/A | |
Completed |
NCT02607319 -
Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure
|
Phase 4 | |
Completed |
NCT01331720 -
Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation
|
N/A | |
Completed |
NCT01331733 -
Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist
|
N/A | |
Not yet recruiting |
NCT02648555 -
A Lifestyle Intervention to Improve in Vitro Fertilization Results
|
N/A | |
Suspended |
NCT00749853 -
Efficacy of Ovarian Stimulation Based on FSHR Genotype Status
|
Phase 3 | |
Recruiting |
NCT03177122 -
Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology
|
Phase 4 | |
Completed |
NCT03169166 -
The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies
|
Phase 4 | |
Completed |
NCT01406964 -
Chlamidia Antibodies Test for Tubal Factor Screening
|
N/A | |
Completed |
NCT01430650 -
Endometrial Priming for Embryo Transfer
|
Phase 4 | |
Completed |
NCT03173404 -
Benefits of Hysteroscopy Prior to Performing a Cycle of in Vitro Fertilization/Intracytoplasmic Sperm Injection
|
N/A | |
Completed |
NCT03561129 -
Embryotransfer Operator and Pregnancy Rate
|
||
Recruiting |
NCT05173597 -
Real-world Evidence on Follitropin Delta Individual Dosing
|
||
Completed |
NCT03619707 -
Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles
|
Phase 4 |